|
|
|
|
Busulfan
|
| |
|
| |
Busulfan is a chemotherapy drug that is a cell cycle non-specific alkylating antineoplastic agent (slows the growth of cancer cells). More specifically it belongs to a subclass of alkylating agents known as alkyl sulfonates. It is marketed in the U.S. by GlaxoSmithKline under the brand name Myleran, and has been in clinical use since 1959. Busulfan is also available in an IV formulation marketed as Busulfex by PDL BioPharma, Inc.

Discussion
Ask a question about 'Busulfan'
Start a new discussion about 'Busulfan'
Answer questions from other users
|
Encyclopedia
Busulfan is a chemotherapy drug that is a cell cycle non-specific alkylating antineoplastic agent (slows the growth of cancer cells). More specifically it belongs to a subclass of alkylating agents known as alkyl sulfonates. It is marketed in the U.S. by GlaxoSmithKline under the brand name Myleran, and has been in clinical use since 1959. Busulfan is also available in an IV formulation marketed as Busulfex by PDL BioPharma, Inc. Its chemical designation is 1,4-butanediol dimethanesulfonate.
History
Busulfan used to be the standard of treatment for Chronic Myeloid Leukemia (CML) until it was replaced with the new gold standard, Imatinib.
Indications
Currently, its main uses are in bone marrow transplantation, especially in chronic myelogenous leukemia (CML), where it is used as a conditioning drug. Busulfan can control tumor burden but cannot prevent transformation or correct cytogenic abnormalities. Though not as common, it may also be used for Chronic Lymphocytic Leukemia (CLL).
The drug was recently used in a study to examine the role of platelet-transported serotonin in liver regeneration.
Availabilty
Myleran is supplied in white film coated tablets with 2mg of Busulfan per tablet.
Side effects
Toxicity may include interstitial pulmonary fibrosis, hyperpigmentation, seizures, hepatic (veno-occlusive disease) and wasting syndrome. Phenytoin may be used concurrently to prevent the seizures.
1,4-Butanediol dimethanesulfonate is listed by the IARC as a Group 1 carcinogen.
Pharmacology Its mechanism of action through alkylation produces Guanine-Guanine intrastrand crosslinks. This occurs through an SN2 reaction in which the relatively nucleophilic guanine N7 attacks the carbon adjacent to the mesylate leaving group. This kind of damage cannot be repaired by cellular machinery and thus the cell undergoes apoptosis.
Busulfan also induces thrombocytopenia, a condition of lowered blood platelet count and activity.
External links
- (PDF prescribing information)
- (PDF prescribing information)
-
|
| |
|
|